StockData
Coherus Oncology, Inc. logo

Coherus Oncology, Inc. (CHRS) stock

CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/3067% below fair value
$0.39−0.02 (-5.56%)

Close on Nov 19, 2026Market cap $59.81MP/E –Yield –

Coherus Oncology free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Coherus Oncology's free cash flow for the twelve months ending Dec 31, 2023 was -$175.17M. For fiscal 2023 it was -$175.17M. The highest annual figure on record is $146.91M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2023Dec 31, 2023-$175.17M–
FY2022Dec 31, 2022-$243.16M–
FY2021Dec 31, 2021-$38.72M-126.4%
FY2020Dec 31, 2020$146.91M+453.7%
FY2019Dec 31, 2019$26.53M–
FY2018Dec 31, 2018-$160.06M–
FY2017Dec 31, 2017-$204.86M–
FY2016Dec 31, 2016-$259.06M–
FY2015Dec 31, 2015-$114.15M–
FY2014Dec 31, 2014-$26.78M-277.9%
FY2013Dec 31, 2013$15.05M–
FY2012Dec 31, 2012-$20.03M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2023Dec 31, 2023-$12.97M–
Q3 FY2023Sep 30, 2023-$54.30M–
Q2 FY2023Jun 30, 2023-$39.02M–
Q1 FY2023Mar 31, 2023-$68.88M–
Q4 FY2022Dec 31, 2022-$100.04M–
Q3 FY2022Sep 30, 2022-$37.55M-379.2%
Q2 FY2022Jun 30, 2022-$50.92M–
Q1 FY2022Mar 31, 2022-$54.66M-4573.0%
Q4 FY2021Dec 31, 2021-$52.79M-264.1%
Q3 FY2021Sep 30, 2021$13.45M-70.3%
Q2 FY2021Jun 30, 2021-$603.00K-101.0%
Q1 FY2021Mar 31, 2021$1.22M-89.6%
Q4 FY2020Dec 31, 2020$32.17M+85.7%
Q3 FY2020Sep 30, 2020$45.24M-16.3%
Q2 FY2020Jun 30, 2020$57.81M+362.6%
Q1 FY2020Mar 31, 2020$11.69M–
Q4 FY2019Dec 31, 2019$17.32M–
Q3 FY2019Sep 30, 2019$54.03M–
Q2 FY2019Jun 30, 2019$12.50M–
Q1 FY2019Mar 31, 2019-$57.32M–
Q4 FY2018Dec 31, 2018-$47.58M–
Q3 FY2018Sep 30, 2018-$43.28M–
Q2 FY2018Jun 30, 2018-$35.54M–
Q1 FY2018Mar 31, 2018-$33.67M–
Q4 FY2017Dec 31, 2017-$30.03M–
Q3 FY2017Sep 30, 2017-$43.33M–
Q2 FY2017Jun 30, 2017-$56.54M–
Q1 FY2017Mar 31, 2017-$74.97M–
Q4 FY2016Dec 31, 2016-$90.46M–
Q3 FY2016Sep 30, 2016-$62.45M–

More Coherus Oncology figures

See a number that looks wrong?